Coronex has developed a platform for lateral flow (LF) testing that detects new COVID-19 variants.
Accurate repeat testing, such as that provided by the new Coronex LF technology, will enable monitoring of antibody responses to vaccination over time, and inform the need for repeat immunisation over the coming months and years.
This proprietary platform technology has been used to develop highly optimised LF tests for SARS-Cov-2 antibodies. The technology also allows the LF tests to be adapted easily and rapidly to detect antibodies to newly isolated variants when mutations arise.
The technology has been developed and tested over six months on a cohort of COVID-19 samples provided by the NHS Greater Glasgow and Clyde Biorepository Network.
Coronex was set up in April 2020 to address unmet needs in LF antibody testing. It has brought together experts in the development of large-scale test and antigen manufacture.
Partners in the Coronex collaboration are Scottish Health Innovations (SHIL), representing NHS Greater Glasgow & Clyde, together with a number of Scottish and UK-based biotechnology industry partners – Excivion, Lateral Dx, Activotec, The Antibody Company and Glasgow-based investment partner Axon Healthcare Investments.
Eric Wagner, director of The Antibody Company, said: “We are in no doubt that the Coronex platform has re-engineered and revolutionised lateral flow technology.
“The adaptability of the technology is vitally important when we see the rapid spread of the new coronavirus variants; and whilst our primary focus has been on SARS-CoV-2, the same core technology could have applications for other infectious agents, or in detecting auto-antibodies in autoimmune disorders or monitoring therapeutic antibodies used as drug treatments.
“We have proven the technology works and with further investment can accelerate translation into widespread clinical use.”
Coronex is now seeking an investment partner that can support further development and validation, bring this innovative test into early clinical use, and extend the technology to other diagnostic areas.
Graham Watson, executive chairman of SHIL, said: “The rapid research and development efforts of a homegrown team of experts, combined with the regulatory and commercial expertise of Scottish Health Innovations, has brought Coronex to the stage of patent application.
“It is a vital breakthrough that we are immensely proud to be part of.”